Viking Therapeutics’ VK2735 continues to demonstrate significant weight loss potential in clinical trials. New data from both Phase 1 and Phase 2 trials highlight the drug’s ability to induce substantial weight reduction and improve metabolic parameters. The company is evaluating both subcutaneous and oral formulations, demonstrating the versatility of VK2735 as a potential treatment for obesity.